[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342576-105":59,"doc-detail-342576-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-triple-negative-breast-cancer-stem-cells-using-nanocarriers","Targeting triple-negative breast cancer stem cells using nanocarriers","","Breast cancer is a complex, heterogeneous disease grouped by molecular receptor status into luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC). TNBC, about 20% of cases, lacks ER/PR/HER2 and is refractory to targeted therapies, with aggressive progression, frequent recurrence, and chemotherapy resistance. Tumor initiation, progression, and treatment resistance are linked to breast cancer stem cells (BCSCs) with self-renewal and tumorigenic potential. This review discusses key BCSC targets and nanocarrier strategies to overcome off-target effects and improve treatment outcomes by delivering anti-BCSC agents with enhanced efficacy and reduced systemic toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-triple-negative-breast-cancer-stem-cells-using-nanocarriers/342576/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-triple-negative-breast-cancer-stem-cells-using-nanocarriers/342576.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is triple-negative breast cancer difficult to treat compared with other breast cancer subtypes?","Question",{"text":112,"@type":113},"TNBC lacks ER, PR, and HER2, so it does not respond to targeted therapies. It is associated with aggressive behavior, higher recurrence rates, and resistance to chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do breast cancer stem cells contribute to TNBC progression and treatment resistance?",{"text":117,"@type":113},"BCSCs have self-renewal and tumorigenic potential, resist conventional therapies, and can regenerate heterogeneous tumor cell populations. Their survival after chemotherapy can drive relapse and recurrence.",{"name":119,"@type":110,"acceptedAnswer":120},"What targeting challenges are discussed for anti-BCSC agents, and how do nanocarriers help?",{"text":121,"@type":113},"Challenges include off-target effects, low solubility, and limited bioavailability. Nanoparticle-based therapies are presented as a promising approach to deliver targeted treatments to BCSCs while minimizing systemic toxicity and improving efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342576,1790179978,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Review  \nTargeting triple negative breast cancer stem cells using nanocarriers  \nNagasen Dasari1,2,3 · Girija Sankar Guntuku1 · Sai Kiran S. S. Pindiprolu2,3  \nReceived: 11 October 2023 / Accepted: 27 February 2024  \n© The Author(s) 2024 OPEN  \nAbstract  \nBreast cancer is a complex and heterogeneous disease, encompassing various subtypes characterized by distinct molecular features, clinical behaviors, and treatment responses. Categorization of subtypes is based on the presence or absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), leading to subtypes such as luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC). TNBC, comprising around 20% of all breast cancers, lacks expression of ER, PR, and HER2 receptors, rendering it unresponsive to targeted therapies and presenting significant challenges in treatment. TNBC is associated with aggressive behavior, high rates of recurrence, and resistance to chemotherapy. Tumor initiation, progression, and treatment resistance inTNBC are attributed to breast cancer stem cells (BCSCs), which possess self-renewal, differentiation, and tumorigenic potential. Surface markers, self-renewal pathways (Notch, Wnt, Hedgehog signaling), apoptotic protein (Bcl-2), angiogenesis inhibition (VEGF inhibitors), and immune modulation (cytokines, immune checkpoint inhibitors) are among the key targets discussed in this review. However, targeting the BCSC subpopulation in TNBC presents challenges, including off-target effects, low solubility, and bioavailability of anti-BCSC agents. Nanoparticle-based therapies offer a promising approach to target various molecular pathways and cellular processes implicated in survival of BSCS in TNBC. In this review, we explore various nanocarrier-based approaches for targeting BCSCs inTNBC, aiming to overcome these challenges and improve treatment outcomes for TNBC patients. These nanoparticle-based therapeutic strategies hold promise for addressing the therapeutic gap in TNBC treatment by delivering targeted therapies to BCSCs while minimizing systemic toxicity and enhancing treatment efficacy.  \nKeywords Breast cancer stem cells · Molecular targets · Nano carriers · Anti-BSCS agents  \n1 Introduction  \nBreast cancer is a common and highly prevalent cancer subtype globally according to world health organization [1–3] . Breast cancer has been identified as a significant contribution to mortality rates trailing closely behind lung cancer. Based on the most recent data available around 2.5 million women were diagnosed with breast cancer annually resulting in approximately 685,000 deaths world-wide [4] .  \nTNBC constitute around 20% among all breast cancer cases and it is characterized by the absence of ER, PR, and HER2 receptors. It presents a highly aggressive phenotype, tends to metastasize more, and frequently acquires resistance to chemotherapy. As per reports in 2023, a substantial number of cases ofTNBC were recorded, reaching approximately  \n* Nagasen Dasari, [nagasenpharma@gmail.com |](nagasenpharma@gmail.com |1Andhra University College of Pharmaceutical)[1](nagasenpharma@gmail.com |1Andhra University College of Pharmaceutical)[Andhra University College of Pharmaceutical](nagasenpharma@gmail.com |1Andhra University College of Pharmaceutical) Sciences, Andhra University, Vishakhapatnam, Andhra Pradesh, India. 2Aditya Pharmacy College, Surampalem, Andhra Pradesh, India. 3Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh, India.  \nDiscover Nano  \n(2024) 19:41  \n| [https://doi.org/10.1186/s11671-024-03985-y](https://doi.org/10.1186/s11671-024-03985-y)  \n2,088,849. These statistics highlight the significant prevalence ofTNBC as a type of cancer affecting women. According to available treatment data, TNBC has a mean survival rate of approximately 10.2 months. For cases where the tumour is localized in regional areas, the 5-year survival rate reaches 65% . However, when ","cbCails2A5jqmGmC","https://ap.wps.com/l/cbCails2A5jqmGmC","pdf",1188042,29,"English","# Introduction\n# Triple-negative breast cancer overview\n## Treatment challenges: metastasis and chemoresistance\n# Breast cancer stem cells in TNBC\n## Self-renewal, quiescence, and DNA repair\n## Role in recurrence and metastasis via EMT\n# Targeting strategies for BCSCs","[{\"question\":\"Why is triple-negative breast cancer difficult to treat compared with other breast cancer subtypes?\",\"answer\":\"TNBC lacks ER, PR, and HER2, so it does not respond to targeted therapies. It is associated with aggressive behavior, higher recurrence rates, and resistance to chemotherapy.\"},{\"question\":\"How do breast cancer stem cells contribute to TNBC progression and treatment resistance?\",\"answer\":\"BCSCs have self-renewal and tumorigenic potential, resist conventional therapies, and can regenerate heterogeneous tumor cell populations. Their survival after chemotherapy can drive relapse and recurrence.\"},{\"question\":\"What targeting challenges are discussed for anti-BCSC agents, and how do nanocarriers help?\",\"answer\":\"Challenges include off-target effects, low solubility, and limited bioavailability. Nanoparticle-based therapies are presented as a promising approach to deliver targeted treatments to BCSCs while minimizing systemic toxicity and improving efficacy.\"}]","Targeting triple-negative breast cancer stem cells using nanocarriers | PDF",1790047230,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65f833ecc855371c7c793f328d5a97be.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bc208a785b9454c4dbd85a99be66bb2.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67a6ff46bd04082dae826be89b444d42.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/231d82b020c637aae896637e324ccca3.webp",980,1301]